Drug Utilization Study of Diuretics in Children with Hydrocephalus

  • Yen Yen Ari Indrawijaya Universitas Islam Negeri Maulana Malik Ibrahim
  • Sumarno Sumarno Universitas Airlangga
  • Wihasto Suryaningtyas Dr. Soetomo Hospital http://orcid.org/0000-0002-1187-3777
  • Nuril Auliya Husna Dr. Soetomo Hospital


Hydrocephalus is a condition characterized by a dynamic imbalance between formation and absorption of cerebrospinal fluid that increases the size of intracranial space of the brain and, in some situations, an extension of the outer space of the brain with or without increased ventricular size. This study aimed to examine the use of diuretics and identify drug therapy problems in hospitalized children with hydrocephalus through the medical record. The study design is observational retrospective with time-limited sampling based on data in medical records at 2010-2013 periods, found 17 of 70 patients using diuretics therapy. There are three categories of diuretic which are used were mannitol (70.6%), acetazolamide (23.5%), and a combination of mannitol and acetazolamide (5.9%). Diuretics can be used for pre-op, post-op, and pre & post-op on all types of hydrocephalus. Still, the specific use of diuretics may be caused by variations in comorbid diagnoses, clinical data, and laboratory data for each patient. Adverse drug reactions are potentially dominant in DTP analysis, and these are 7 of 17 patients. Monitoring of serum electrolytes such as sodium and potassium is needed because it decreases are potential adverse drug reactions of diuretics.

Author Biographies

Yen Yen Ari Indrawijaya, Universitas Islam Negeri Maulana Malik Ibrahim

Department of Pharmacy, Faculty of Medical and Health Sciences, Universitas Islam Negeri Maulana Malik Ibrahim, Malang, Indonesia

Sumarno Sumarno, Universitas Airlangga

Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia

Wihasto Suryaningtyas, Dr. Soetomo Hospital

Neurosurgery Department, Dr. Soetomo Hospital, Surabaya, Indonesia

Nuril Auliya Husna, Dr. Soetomo Hospital

Pharmacy Installation, Dr. Soetomo Hospital, Surabaya, Indonesia


1. Paste HL. A Contemporary Definition and Classification of Hydrocephalus. Neurol Pediatric Semin . 2009; 16:9-15.
2. Satyanegara H, Abubakar S, Maulana AJ, Sufarnap E, Benhadi I, Saputra A, Satyanegara Neurosurgery. 4th Edition. Jakarta: PT Gramedia Pustaka Utama. 2010.p. 347-57.
3. Indonesian Ministry of Health. Basic Health Research. Jakarta: Agency for Health Research and Development, Ministry of Health, Republic of Indonesia. 2008.
4. Rizvi R, Anjum Q. Hydrocephalus in children. TJ of Pakistan Med. 2005 ; 55(11): 502-7.
5. Sivagnanam M, Jha NK. Hydrocephalus: An overview. In: DS, Pant, and I., Cherlian, Hydrocephalus . USA: In Tech. 2012. p.1-16.
6. Poca M, Sahuquillo J. Short-term medical management of hydrocephalus. PubMed. 2005; 9:1525-38.
7. Vorst MMJV, 2007. Diuretics in pediatrics: current knowledge and future prospects. In: Vorst, Van der, Optimal Furosemide Therapy in Critically Ill Infants. Europ J. of Ped . 2007: 31-72.
8. Wells TG, Fasules JW, Taylor BJ, Kearns GL. Pharmacokinetics and Pharmacodynamics of Bumetanide in Neonates Treated With Extracorporeal Membrane Oxygenation . J. Pediatrics . 1992; 121(6): 974-80.
9. Murshid WR, Jarallah JS, Dad MI. Epidemiology of infantile hydrocephalus in Saudi Arabia: birth prevalence and associated factors. Pediatric Neurosurgery. 2000; 32(3): 119-23.
10. Shakeri M, Vahedi P, Lotfiria I. A review of hydrocephalus: history, etiologies, diagnosis, and treatment. Neurosurg Q. 2008; 8(3): 216-220.
11. Jaddoa M, 2010. The association of acquired hydrocephalus with different brain diseases in Babylon. Pur and App Sci. 2010; 18(15): 2034-2039.
12. Seldin D, Giebisch G. Diuretic Agents. 1 st Ed. USA: Academic Press. 1997. p. 549-58.
13. Carrion E, Hertzog JH, Medlock MD, Hauser G, Dalton HJ. Use of acetazolamide to decrease cerebrospinal fluid production in chronically ventilated patients einth ventriculopleural shunts. Arch Dis Child ; 2001; 84:68-71.
14. BMJ Group. British National Formulary (BNF) for Children . London: BMJ Group and Royal Pharmaceutical Society of Great Britain. 2009. p. 103-4, 633-4.
15. Dewanto G, Suwono WJ, Riyanto B, Turana Y. Practical Guide to Diagnosis & Management of Neurological Diseases . 1st Edition. Jakarta: EGC Medical Book Publisher. 2009. p. 160-3.
16. Uchino S, Bellomo R, Goldsmith D, Bates S, Ronco C. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med . 2006; 34(7): 1913-7.
17. Tornechko MA, Strand LM, Morley PC, Cipolle RJ. Q and A from Pharmaceutical care project in Minnesota. Am Pharm . 1995; 35(4): 30-9.
18. Morris GC, Egam JG, Jones MK. Hypokalemic paralysis included by bolus of prednisolone in Graves' disease. Aust NJ Med . 1992; 22:132.
19. Ropper AH. Hyperosmolar therapy for raised intracranial pressure. N Eng J Med. 2012; 367(746): 746-752.
20. Lee A. Adverse Drug Interaction . 2 nd Ed. Glasgow: Pharmaceutical Press. 2006. p. 158, 183.
21. Aronso JK. Meyler's Side Effects of Cardiovascular Drugs . 15 th Ed. . New York: Elsevier. 2009. p.197.
How to Cite
INDRAWIJAYA, Yen Yen Ari et al. Drug Utilization Study of Diuretics in Children with Hydrocephalus. Proceedings of International Pharmacy Ulul Albab Conference and Seminar (PLANAR), [S.l.], v. 1, p. 77-87, dec. 2021. ISSN 2827-7848. Available at: <http://conferences.uin-malang.ac.id/index.php/planar/article/view/1497>. Date accessed: 19 aug. 2022. doi: https://doi.org/10.18860/planar.v1i0.1497.